CSF3 and acute myeloid leukemia: Moreover, venetoclax combined with cytarabine, fludarabine, idarubicin, and granulocyte colony-stimulating factor correlated with deep remission rates and improved survival rates after hematopoietic stem cell transplantation (HSCT), demonstrating this to be an effective intensive treatment regimen for patients with ND-AML or R/R AML [60].